Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment

NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth

(2015) Xiaojun Zha et al.   CANCER LETTERS

Spatial Control of the TSC Complex Integrates Insulin and Nutrient Regulation of mTORC1 at the Lysosome

(2014) Suchithra Menon et al.   CELL

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

A Novel Mechanism by Which Tissue Transglutaminase Activates Signaling Events That Promote Cell Survival

(2014) Lindsey K. Boroughs et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

(2014) Hui Jun Lim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Simultaneously Targeting Tissue Transglutaminase and Kidney Type Glutaminase Sensitizes Cancer Cells to Acid Toxicity and Offers New Opportunities for Therapeutic Intervention

(2014) William P. Katt et al.   MOLECULAR PHARMACEUTICS

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

(2014) C. A. Martz et al.   Science Signaling

Genetic and Pharmacologic Inhibition of mTORC1 Promotes EMT by a TGF- -Independent Mechanism

(2013) I. Mikaelian et al.   CANCER RESEARCH

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies

(2013) Akio Iwanami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NFκB) Signaling Controls Basal and DNA Damage-induced Transglutaminase 2 Expression

(2012) Lingbao Ai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance

(2012) Bao Hoang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1

(2012) Christian C. Dibble et al.   MOLECULAR CELL

Tissue transglutaminase: a new target to reverse cancer drug resistance

(2011) Alfredo Budillon et al.   AMINO ACIDS

Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress

(2011) Shukie Ng et al.   Autophagy

Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor

(2011) Yi Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase

(2011) M. Khanna et al.   MOLECULAR CANCER THERAPEUTICS

TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2

(2011) M. Delhase et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of mTOR inhibitor resistance in cancer therapy

(2011) Jennifer S. Carew et al.   Targeted Oncology

Transglutaminase 2: a multi-functional protein in multiple subcellular compartments

(2010) Donghyun Park et al.   AMINO ACIDS

Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer

(2010) Kapil Mehta et al.   BIOCHEMICAL PHARMACOLOGY

Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5

(2010) Manuela Frese-Schaper et al.   FEBS LETTERS

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells

(2010) Anupam Kumar et al.   PLoS One

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Common corruption of the mTOR signaling network in human tumors

(2009) S Menon et al.   ONCOGENE

Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells

(2009) G -Y Jang et al.   ONCOGENE

Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling

(2008) L. Cao et al.   CARCINOGENESIS

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

(2008) Paolo Baldo et al.   CURRENT CANCER DRUG TARGETS

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE